Another Regeneron Bear is Born
October 20, 2017 at 15:57 PM EDT
Shares of Regeneron are falling today after an analyst at Barclays warned that expectations surrounding the eczema drug Dupixent are too high. Here's why.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.